Physician profile
Frederic Kelley
NPI 1659472249
$2,029.71
in general payments reported to CMS, 2019-2025
23 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $134 · 2021: $270 · 2022: $351 · 2023: $473 · 2024: $371 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $449.22 | 2020-2025 | Acuvue |
| Oyster Point Pharma, INC. | $288.98 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $268.43 | 2019-2025 | Rocklatan, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $222.20 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.96 | 2019-2021 | |
| Allergan, INC. | $113.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $98.66 | 2019-2023 | |
| Shire North American Group INC | $56.86 | 2019 | |
| Abbvie INC. | $50.51 | 2022-2023 | |
| Amgen INC. | $42.92 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $38.70 | 2024-2025 | Xdemvy |
| Coopervision INC. | $38.40 | 2024 | Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $34.21 | 2021 | |
| Optovue, INC. | $28.85 | 2020 | |
| Dompe US, INC. | $25.21 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $21.71 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $21.10 | 2022 | |
| Rayner Intraocular Lenses Limited | $20.60 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Menicon America INC | $16.92 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.75 | 2024 | |
| Biotissue Holdings INC. | $16.18 | 2024 | |
| Tearlab Corp | $15.52 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.